ICU Medical, Stock Rating Upgraded by Zacks (ICUI)
ICU Medical, (NASDAQ:ICUI) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report released on Thursday. The firm currently has a $66.90 target price on the stock. Zacks‘s price target suggests a potential upside of 4.45% from the stock’s previous close.
In other ICU Medical, news, Director George A. Lopez sold 12,250 shares of ICU Medical, stock on the open market in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $62.57, for a total value of $766,482.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Separately, analysts at Raymond James upgraded shares of ICU Medical, from a “market perform” rating to an “outperform” rating in a research note on Tuesday. They now have a $67.00 price target on the stock. They noted that the move was a valuation call.
Shares of ICU Medical, (NASDAQ:ICUI) traded down 1.37% on Thursday, hitting $63.17. The stock had a trading volume of 37,015 shares. ICU Medical, has a 52-week low of $54.00 and a 52-week high of $74.93. The stock has a 50-day moving average of $59.93 and a 200-day moving average of $59.70. The company has a market cap of $964.4 million and a P/E ratio of 26.74.
ICU Medical, (NASDAQ:ICUI) last announced its earnings results on Monday, August 11th. The company reported $0.38 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.34 by $0.04. The company had revenue of $78.70 million for the quarter, compared to the consensus estimate of $74.13 million. During the same quarter last year, the company posted $0.48 earnings per share. ICU Medical,’s revenue was up .1% compared to the same quarter last year. Analysts expect that ICU Medical, will post $1.40 EPS for the current fiscal year.
ICU Medical, Inc is engaged in the development, manufacture and sale of medical devices used in infusion therapy, oncology and critical care applications.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.